In March, shortly after the US launch of Serono SA 's multiple sclerosis treatment interferon beta-1a (Rebif) the company's chairman and CEO, Ernesto Bertarelli, dismissed rumors of a possible co-promotion with Pfizer Inc. So what changed between then and July 11th, when the two companies announced that they would indeed be joining forces to promote Rebif in the United States as part of a deal that netted Serono a $200 million up-front payment in exchange for an undisclosed percent of the drug's proceeds? [See Deal]
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?